Most Recent
Seven has gone on the offensive in a lawsuit by former Spotlight producer Taylor Auerbach that alleges the broadcaster breached a settlement deed and defamed him, arguing it was Auerbach who broke the terms of their agreement.
Former Spotlight producer Taylor Auerbach, who is suing his former employer over its statements that he was disciplined for his dealings with Bruce Lehrmann, claims the comments cost him his job at Sky News.
A court has allowed Ben Roberts-Smith to admit into evidence a secret recording of Nine journalist Nick McKenzie, as the former soldier makes a fresh bid to revive his failed defamation case.
Nine journalist Nick McKenzie was pressed during cross-examination on Thursday in Ben Roberts-Smith's bid to re-open his defamation appeal on whether he has used deceptive methods or 'subterfuge' in his reporting.
Two Nine in-house lawyers, as well as senior editors and journalists, are facing a contempt of court bid by individuals who are the subject of a suppression order in journalist Antoinette Lattouf's unfair dismissal case against the ABC.
In new allegations, a former Super Retail Group exec claims she and a fellow whistleblower were threatened by CEO Anthony Heraghty at a mediation and that the company appointed a conflicted law firm to investigate her complaints.
Construction PRO
Property giant Mirvac Group is in talks with a potential capital partner for its Harbourside development in Sydney, as it progresses construction on the major waterfront project.
Ben Roberts-Smith has accused Nine journalist Nick McKenzie of using his lawyers as a "shield" against claims he had access to confidential and privileged legal strategy in the former soldier's failed defamation case.
Court approval of a $50 million settlement in a class action against ANZ and superannuation trustee OnePath has been delayed, after 22,000 group members were excluded from an opt-out notice due to a problem with OnePath's computing process.
Drug giant Sanofi has failed in its appeal of a decision granting applications by biopharmaceutical company Amgen for patents covering the cholesterol-lowering treatment Repatha.